Sarepta (SRPT) Q1 2026 Earnings Transcript

Sarepta reported Q1 revenue of $731 million, down 2% year over year, but posted a GAAP operating profit of $358 million, non-GAAP operating profit of $398 million, and ended the quarter with $748 million in cash and investments. Management reiterated 2026 revenue guidance of $1.2 billion to $1.4 billion and said the base business remains profitable and cash-flow positive, while early siRNA data in FSHD and DM1 looked encouraging. The key offset is that Alevitus sales were soft at $102 million and management kept a cautious stance on near-term growth, but the balance sheet and pipeline remain solid.

Analysis

SRPT is transitioning from a “story stock” to a cash-generating platform with multiple shots on goal, and that matters more than the headline revenue miss. The market is likely still underappreciating the second-order effect of a profitable base business funding a broad pipeline without dilution; that removes a common biotech overhang and should compress the financing-risk discount over the next 6-12 months. The key issue is not whether Alevitus can grow immediately, but whether current commercial softness is a temporary information lag that later converts into a higher durable run-rate.

The biggest incremental upside catalyst is the possibility that the non-ambulatory strategy reopens a previously constrained label segment. If the sirolimus pre-treatment data continue to show no liver-enzyme signal, SRPT could move from damage control to expansion in a population that has been economically excluded, which would improve both the near-term revenue base and long-duration franchise value. That said, this is still a multi-step regulatory/clinical sequence, so the market will likely re-rate only on repeated evidence rather than one clean readout.

On the pipeline, the differentiated delivery story in FSHD/DM1 is more important than the first efficacy print itself. If muscle exposure keeps tracking above competitors without dose-limiting toxicity, SRPT can plausibly become the reference name in RNA delivery, which would force competitors to spend more on dose escalation and safety work. The contrarian risk is that investors may over-rotate into the early science and underweight the long regulatory path; the next 2-3 quarters should be dominated by data quality, not commercial inflection.

Net/net, the setup is constructive but asymmetric: downside is cushioned by cash generation and guidance discipline, while upside depends on a series of binary but increasingly de-risked catalysts. The stock should behave better on any confirmation that commercial troughing has ended, but the more interesting move is likely a higher-quality multiple as execution risk declines and pipeline optionality becomes internally funded.

Key Decisions for Investors

• Long SRPT on a 3-6 month horizon ahead of the next siRNA and sirolimus data milestones; risk/reward is attractive because balance-sheet risk is now low and upside comes from multiple independent catalysts rather than a single program.
• Buy SRPT call spreads into weakness: target the next 2 quarterly updates as the window for commercial stabilization evidence; upside is driven by a re-rating if Alevitus demand inflects while downside is partly protected by guidance.
• Pair trade: long SRPT / short a higher-financing-risk small-cap biotech basket over 6 months; the thesis is that internally funded pipeline execution should outperform names that still need capital markets access.
• If sirolimus Cohort 8 data confirm no ALI signal, add to SRPT immediately on a 1-2 week catalyst window; that result would reopen a meaningful patient segment and likely force upward revision of long-term Duchenne franchise assumptions.
• Trim or hedge if the next commercial print fails to show sequential Alevitus improvement despite salesforce expansion; that would suggest the information-gap thesis is not converting, and the market may refocus on execution risk.